Type of Mesothelioma:
Validation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models
Scientific Reports 2026 February 11 [Link] Huaikai Shi, Sakthi Priya Selvamani, Richard Zelei, Ling Zhuang, Dongwei Wang, Ben Johnson, Vivek Dharwal, Duo Xu, Yiwei Wang, Tristan Rutland, Sonja Klebe, Steven Kao, Anthony Linton, Elham Hosseini-Beheshti, Yuen Yee Cheng Abstract Pleural mesothelioma (PM) is a highly aggressive cancer with limited treatment efficacy and poor prognosis. Conventional…
Read MoreFeasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma
Translational Lung Cancer Research 202t6 January 31 [Link] Moshe Lapidot, Emanuele Mazzola, Raphael Bueno Abstract Background: Pleural mesothelioma (PM) represents an uncommon and exceptionally lethal malignancy. The sarcomatoid subtype constitutes the rarest histological variant, traditionally linked to the worst prognosis, while the advantages of operative intervention remain inadequately established. In this study, we present findings…
Read MoreConstruction and validation of a prognostic risk score model for malignant mesothelioma
Discover Oncology 2026 February 8 [Link] Qingzheng An, Fengyun Cui, Guangming Shi, Longkun Ni, Kun Xiao, Feng Tian, Yuezhi Chen, Leping Li, Changqing Jing, Guodong Lian Abstract Purpose: Malignant mesothelioma is a rare, aggressive cancer. Although the World Health Organization (WHO) histologic subtypes–epithelioid (best prognosis), biphasic, and sarcomatoid (worst prognosis)—provide baseline stratification, architectural and molecular…
Read MoreDisaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 February 2 [Link] Shubham Gulati, Andrea Wolf, Jai Mehrotra-Varma, Stephanie Tuminello, Emanuela Taioli, Raja Flores Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS2) trial has drawn into question pleurectomy/decortication (PD) for the treatment of pleural mesothelioma. This trial’s evaluation of resectability (poor positron emission tomography/computed tomography utilization, patients…
Read MoreNeoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases
The American Journal of Case Reports 2026 February [Link] Arnaldo Urbano-Ruiz, Bruna Latronico Palma, Ronaldo Elias Carnut Rego, Daniel Bianqui Guaraldo da Silva, Bianca Fava, Erlan Araujo Falcão , Michelle Louise Rodrigues Barbosa da Silva, Julia Rodrigues Leandro Uliano Abstract BACKGROUND Peritoneal mesothelioma (PM) is the second most common presentation site of malignant mesothelioma. The…
Read MoreAdverse Renal Outcomes in Patients With Mesothelioma-A Territory-Wide Real-World Data
Cancer Medicine 2026 February [Link] Wang Chun Kwok, James Chung Man Ho, Isaac Sze Him Leung, Desmond Yat Hin Yap Abstract Introduction: Advances in mesothelioma management have translated into longer patient survival and different treatment-related side effects including nephrotoxicity. The risk of developing adverse renal outcomes in patients with mesothelioma and associated risk factors remains…
Read MoreClinical applications of cryobiopsy in the diagnosis of thoracic malignancies: a comprehensive review
Japanese Journal of Clinical Oncology 2026 January 30 [Link] Miwa Kamatani, Nobuyasu Awano, Takehiro Izumo Abstract Accurate histopathological and molecular characterization of lung cancer is essential for optimal treatment selection in the era of precision medicine. While conventional biopsy techniques are widely available and safe, they often yield small tissue samples with crush artifacts that…
Read MoreTreatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007-2020
Advances in Therapy 2026 March [Link] Himani Aggarwal, Ashwini Arunachalam, Jae Min, Yu-Han Kao, Haidong Feng, Danmeng Huang, Gloria Odonkor Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare malignancy typically attributed to occupational asbestos exposure and associated with dismal survival outcomes. The standard of care for unresectable MPM was platinum-based chemotherapy until the approval…
Read MorePembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial
Clinical Lung Cancer 2026 March [Link] Tetsuya Takagawa, Kanae Takahashi, Yuji Orimoto, Yukie Morisaki, Shinichiro Suna, Takashi Daimon, Takashi Kijima, Kozo Kuribayashi Abstract Background: In pleural mesothelioma (PM), platinum-based chemotherapy and immune checkpoint inhibitors including nivolumab and ipilimumab have been approved but have not shown sufficient therapeutic efficacy, and the development of new therapies is…
Read MoreMechanisms of Chemoresistance in Malignant Pleural Mesothelioma: The Regulatory Role of miRNAs
Archives of Medical Research 2026 January 27 [Link] Andrea Martinez-Marroquin, Javier Gaytán-Cervantes, Haydeé Rosas-Vargas, Constantino López-Macías, Itzel Peralta-Salguero, Miguel Cid-Soto, Violeta Castro Leyva, Marlon De Ita, Carolina González-Torres Abstract Malignant pleural mesothelioma (MPM), is a rare and aggressive cancer that originates in the mesothelium lining the lungs. It is considered an occupational disease associated with…
Read More
Skip to content